Oligonucleotides-A Novel Promising Therapeutic Option for IBD.

Scarozza, Patrizio; Schmitt, Heike; Monteleone, Giovanni; Neurath, Markus F; Atreya, Raja

Scarozza, Patrizio; Schmitt, Heike; Monteleone, Giovanni; Neurath, Markus F; Atreya, Raja.

Afiliación

Scarozza P; Department of Systems Medicine, Gastroenterology, University of Tor Vergata, Rome, Italy.
Schmitt H; Department of Medicine 1, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany.
Monteleone G; Department of Medicine 1, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany.
Neurath MF; Department of Systems Medicine, Gastroenterology, University of Tor Vergata, Rome, Italy.
Atreya R; Department of Medicine 1, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany.

Front Pharmacol ; 10: 314, 2019.

Article en En | MEDLINE | ID: mdl-31068803

Palabras clave

Crohn disease; IBD; antisense oligonucleotide (ASO); target therapies; ulcerative colitis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2019 Tipo del documento: Article País de afiliación: Italia